The DiaFitus Blog
Diabetes news, exercise, nutrition and gadgets, plus updates on the DiaFitus app.
Type 2 Diabetes Remission: 54% in New Diet-Exercise Trial
A trial in adults under 45 found 54% reached type 2 diabetes remission after 24 weeks of supervised diet and exercise. See what it means and the caveats.
Low Blood Sugar: How to Spot It and Treat It Fast
Learn the signs of low blood sugar, the 15-15 approach for treating a mild low, and when hypoglycemia becomes an emergency that needs glucagon.
Winter Workouts With Diabetes: Staying Active in the Cold
Cold weather can change your glucose, freeze insulin and hide foot problems. Here is how to keep exercising safely with diabetes all winter long.
First Glucose and Ketone Sensor Gets FDA Authorization
The FDA has authorized Abbott's Libre Duo 10 Day, the first wearable to track glucose and ketones together. Here is what it is, who it is for and what is next.
Thanksgiving With Diabetes: A Calm Plate Plan
Thanksgiving with diabetes doesn't need stress. Use the plate method, smart buffet habits and a post-meal walk to enjoy the feast with confidence.
Check Your Glucose Before Every Workout
Why a quick glucose check before exercise matters, and how DiaFitus gives plain-language go, snack or wait guidance based on your medication.
Cardio, Intervals or Weights: Which Moves Glucose Most?
Aerobic, interval and strength exercise affect blood glucose differently. Learn what research suggests and how to plan safer workouts with diabetes.
FDA Approves Kerendia for Type 1 Diabetes Kidney Disease
The FDA has approved finerenone (Kerendia) for adults with chronic kidney disease linked to type 1 diabetes. Here is what the news means and what to ask your care team.
FDA Approves Kerendia for Kidney Disease in Type 1 Diabetes
The FDA has approved finerenone (Kerendia) for adults with chronic kidney disease linked to type 1 diabetes. Here is what the news means and what it doesn't.
Articles are for general information and do not replace advice from your doctor or diabetes care team.